Who are Dexamethasone+ Bupivacaine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CT-guided corticosteroid+ bupivicaine, Triamcinolone + Lidocaine, Kenalog and Sensorcaine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexamethasone-bupivacaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dexamethasone+ Bupivacaine — Competitive Intelligence Brief

Dexamethasone+ Bupivacaine (Dexamethasone+ Bupivacaine) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + Local anesthetic combination. Area: Pain management, Anesthesia, Inflammation.

marketed Corticosteroid + Local anesthetic combination Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine) Pain management, Anesthesia, Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

Dexamethasone+ Bupivacaine (Dexamethasone+ Bupivacaine) — Ain Shams University. Dexamethasone reduces inflammation and immune response while bupivacaine provides local anesthesia by blocking nerve conduction.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dexamethasone+ Bupivacaine TARGET	Dexamethasone+ Bupivacaine	Ain Shams University	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)
CT-guided corticosteroid+ bupivicaine	CT-guided corticosteroid+ bupivicaine	Montefiore Medical Center	marketed	Corticosteroid + local anesthetic combination injection
Triamcinolone + Lidocaine	Triamcinolone + Lidocaine	MetroHealth Medical Center	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (triamcinolone); voltage-gated sodium channels (lidocaine)
Kenalog and Sensorcaine	Kenalog and Sensorcaine	Horizon Health Network	phase 3	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (triamcinolone); Voltage-gated sodium channels (bupivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + Local anesthetic combination class)

Ain Shams University · 1 drug in this class
Horizon Health Network · 1 drug in this class
MetroHealth Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexamethasone+ Bupivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/dexamethasone-bupivacaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab